ImmunoPrecise Antibodies (IPA) Competitors $2.16 -0.15 (-6.49%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.23 +0.07 (+3.43%) As of 07/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. ARCT, BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, and AMRNShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Arcturus Therapeutics (ARCT), Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Arcturus Therapeutics Benitec Biopharma Gossamer Bio COMPASS Pathways Prothena Altimmune Aura Biosciences Cartesian Therapeutics Capricor Therapeutics Amarin Arcturus Therapeutics (NASDAQ:ARCT) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Does the media favor ARCT or IPA? In the previous week, ImmunoPrecise Antibodies had 2 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for ImmunoPrecise Antibodies and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.94 beat ImmunoPrecise Antibodies' score of 0.66 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunoPrecise Antibodies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ARCT or IPA? Arcturus Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Which has higher earnings and valuation, ARCT or IPA? ImmunoPrecise Antibodies has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M2.66-$80.94M-$2.53-5.91ImmunoPrecise Antibodies$24.00M4.12-$20.13M-$1.16-1.86 Do insiders & institutionals believe in ARCT or IPA? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ARCT or IPA more profitable? Arcturus Therapeutics has a net margin of -47.47% compared to ImmunoPrecise Antibodies' net margin of -190.76%. Arcturus Therapeutics' return on equity of -27.41% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% ImmunoPrecise Antibodies -190.76%-88.87%-49.26% Do analysts prefer ARCT or IPA? Arcturus Therapeutics currently has a consensus target price of $54.00, indicating a potential upside of 261.45%. ImmunoPrecise Antibodies has a consensus target price of $4.00, indicating a potential upside of 85.19%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryArcturus Therapeutics beats ImmunoPrecise Antibodies on 12 of the 17 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.72M$2.06B$5.70B$9.50BDividend YieldN/AN/A4.58%4.01%P/E Ratio-1.8637.0728.1020.05Price / Sales4.1211.21429.0189.19Price / CashN/A55.2536.2258.56Price / Book2.329.108.665.87Net Income-$20.13M-$63.59M$3.25B$258.55M7 Day Performance24.86%3.16%4.22%3.73%1 Month Performance94.59%10.15%10.51%11.75%1 Year Performance154.12%6.21%34.40%18.03% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies3.0175 of 5 stars$2.16-6.5%$4.00+85.2%+156.2%$105.72M$24.00M-1.8680News CoverageUpcoming EarningsGap UpARCTArcturus Therapeutics2.1609 of 5 stars$13.31-3.4%$54.00+305.7%-35.0%$360.98M$131.27M-5.26180BNTCBenitec Biopharma1.7723 of 5 stars$13.25+3.7%$23.83+79.9%+22.5%$347.81M$80K-8.7720GOSSGossamer Bio4.0075 of 5 stars$1.53+12.5%$8.25+439.2%+68.8%$347.77M$114.70M-6.65180Positive NewsHigh Trading VolumeCMPSCOMPASS Pathways1.7447 of 5 stars$3.71+1.1%$17.00+358.2%-42.0%$347.11MN/A-1.86120Upcoming EarningsPRTAProthena3.7494 of 5 stars$6.43+0.5%$31.50+389.9%-73.1%$346.11M$137.94M-3.09130ALTAltimmune2.0894 of 5 stars$4.26+2.9%$18.20+327.2%-39.0%$345.53M$20K-3.3850AURAAura Biosciences2.4353 of 5 stars$6.75+5.5%$22.00+225.9%-29.6%$339.32MN/A-3.5550News CoveragePositive NewsRNACCartesian Therapeutics2.3061 of 5 stars$13.06-2.0%$40.00+206.3%-19.6%$338.91M$38.91M-0.2564News CoverageCAPRCapricor Therapeutics2.7488 of 5 stars$7.39-3.3%$22.56+205.2%+59.4%$337.58M$22.27M-5.20101Trending NewsGap DownAMRNAmarin0.2424 of 5 stars$16.10-4.9%$12.00-25.5%-2.7%$333.43M$228.61M-4.42360Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives Benitec Biopharma Alternatives Gossamer Bio Alternatives COMPASS Pathways Alternatives Prothena Alternatives Altimmune Alternatives Aura Biosciences Alternatives Cartesian Therapeutics Alternatives Capricor Therapeutics Alternatives Amarin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
